Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm
11:27am, Tuesday, 09'th Sep 2025
NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Organon & Co. (NYSE: OGN) breached their fiduc
Orogen Royalties Announces Trading on the OTCQB
07:30am, Monday, 08'th Sep 2025
VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading o
Orogen Royalties and South32 Form Generative Base Metals Alliance
07:30am, Thursday, 04'th Sep 2025
All dollar figures expressed in United States dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / September 4, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Compan
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).
Orogen Royalties Reports Q2 2025 Financial Results Based on Carve-out Financial Statements
07:30am, Tuesday, 26'th Aug 2025
VANCOUVER, BC / ACCESS Newswire / August 26, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. (formerly 1537944 BC Ltd.) ("Orogen" or the "Company") is pleased to announce strong revenue and cash fl
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 25'th Aug 2025
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation
10:15am, Wednesday, 13'th Aug 2025
SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased sha
Organon: Valuation Discount Offset By Structural Headwinds
02:22pm, Tuesday, 12'th Aug 2025
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:01am, Tuesday, 12'th Aug 2025
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN vs. HQY: Which Stock Is the Better Value Option?
12:41pm, Friday, 08'th Aug 2025
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
11:59am, Wednesday, 06'th Aug 2025
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new produc
Organon (OGN) Fiscal Q2 Revenue Beats 1%
02:47am, Wednesday, 06'th Aug 2025
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
01:10pm, Tuesday, 05'th Aug 2025
Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of R
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
12:01pm, Tuesday, 05'th Aug 2025
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
09:46am, Tuesday, 05'th Aug 2025
Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.
